A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1
receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as
determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes
Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable
metformin treatment.